• 1
    Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997; 111: 1710-1717.
  • 2
    Goya T, Asamura H, Yoshimura H, et al; Japanese Joint Committee of Lung Cancer Registry. Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer. 2005; 50: 227-234.
  • 3
    Shepherd FA. Induction chemotherapy for locally advanced non-small cell lung cancer. Ann Thorac Surg. 1993; 55: 1585-1592.
  • 4
    Pass HI, Pogrebniak HW, Steinberg SM, Mulshine J, Minna J. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg. 1992; 53: 992-998.
  • 5
    Rosell R, Gómez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994; 330: 153-158.
  • 6
    Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994; 86: 673-680.
  • 7
    Depierre A, Milleron B, Moro-Sibilot D, et al; French Thoracic Cooperative Group. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol. 2002; 20: 247-253.
  • 8
    Nagai K, Tsuchiya R, Mori T, et al; Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg. 2003; 125: 254-260.
  • 9
    Choi NC, Carey RW, Daly W, et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol. 1997; 15: 712-722.
  • 10
    Eberhardt W, Wilke H, Stamatis G, et al. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol. 1998; 16: 622-634.
  • 11
    Thomas M, Rübe C, Semik M, et al. Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer. J Clin Oncol. 1999; 17: 1185-1193.
  • 12
    Katakami N, Nishimura T, Takakura S, et al. Phase II study of combined modality therapy for non-small cell lung cancer patients with pathologically confirmed stage III, N2 disease [in Japanese] (abstract). Haigan. 1999; 39: 536.
  • 13
    Katakami N, Naya R, Nishimura T, et al. Long term results of induction carboplatin (CBDCA) and docetaxel (DOC) with concurrent radiation in early-stage non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 2005; 23( 16 suppl): (abstract 7237).
  • 14
    Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009; 374: 379-386.
  • 15
    Thomas M, Rübe C, Hoffknecht P, et al; German Lung Cancer Cooperative Group. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol. 2008; 9: 636-648.
  • 16
    van Meerbeeck JP, Kramer GW, Van Schil PE, et al; European Organisation for Research and Treatment of Cancer-Lung Cancer Group. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst. 2007; 99: 442-450.
  • 17
    Friedel G, Budach W, Dippon J, et al. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study. J Clin Oncol. 2010; 28: 942-948.
  • 18
    Hehr T, Friedel G, Steger V, et al. Neoadjuvant chemoradiation with paclitaxel/carboplatin for selected stage III non-small-cell lung cancer: long-term results of a trimodality phase II protocol. Int J Radiat Oncol Biol Phys. 2010; 76: 1376-1381.
  • 19
    Betticher DC, Hsu Schmitz SF, Totsch M, et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol. 2003; 21: 1752-1759.
  • 20
    Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2004; 22: 3852-3859.